YOLFTbeta
Korro Bio, Inc.

Korro Bio, Inc.

KRRO · NASDAQ · Healthcare / Biotechnology

13.61USD-0.70 (-4.89%)

Price History

Full chart

Market Stats

Previous Close14.31
Open14.24
Day Range13.19 – 14.24
52-Week Range5.20 – 55.89
Volume78.96K
Market Cap140.04M
P/E (TTM)0.00
Forward P/E0.00
EPS-9.88
Dividend Yield0.00%
Beta2.25
50-Day Avg12.09
200-Day Avg11.66

About

Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Ram Aiyar MBA, Ph.D.
  • Employees57
  • Headquarters60 First Street, Cambridge, MA, United States, 02141, USA
  • Websitehttps://www.korrobio.com

Leadership

  • Dr. Ram Aiyar MBA, Ph.D.CEO, President, Interim CFO, Principal Financial Officer & Director · b. 1978
  • Dr. Jean-Francois Formela M.D., MBACo-Founder & Director · b. 1957
  • Dr. Loic Vincent Ph.D.Chief Scientific Officer
  • Dr. Jeffrey M. Cerio J.D., Pharm.D.Senior VP, General Counsel & Corporate Secretary
  • Dr. Andrew Fraley Ph.D.Co-Founder & Advisor
  • Dr. Joshua Rosenthal Ph.D.Co-Founder & Advisor
  • Mr. Todd Chappell M.B.A.Chief Operating Officer · b. 1973
  • Mr. Oliver DolanSenior VP of Finance & Principal Accounting Officer · b. 1983
  • Ms. Stephanie EngelsChief People Officer
  • Dr. Gaozhong Zhu Ph.D.SVP of Chemistry, Manufacturing and Controls & Technical Operations

Financials

Income Statement

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--28.95M36.98M14.07M002.27M6.39M
Growth (%)---+27.76%-61.96%-100.00%--+181.46%
Cost of Revenue531.00K654.00K16.81M1.58M3.84M2.51M3.63M3.56M4.28M
Gross Profit-531.00K-654.00K12.13M35.40M10.23M-2.51M-3.63M2.27M2.11M
Gross Margin--41.92%95.73%72.70%--100.00%33.04%
Operating Expense15.78M18.29M32.81M62.95M45.72M56.49M80.90M94.18M89.45M
Operating Income-16.31M-18.94M-20.68M-27.55M-35.49M-59.00M-84.53M-91.91M-87.34M
Operating Margin---71.42%-74.49%-252.30%---4047.12%-1366.43%
EBITDA-19.53M-18.41M-17.93M-24.90M-33.90M-56.49M-80.90M-88.34M-83.06M
EBITDA Margin---61.95%-67.32%-240.97%---3890.14%-1299.47%
Net Income-20.24M-19.17M-18.75M-26.51M-21.96M-58.03M-81.17M-83.58M-117.26M
Net Income Margin---64.76%-71.68%-156.09%---3680.36%-1834.48%
R&D11.79M11.58M18.33M36.66M23.80M42.20M57.25M63.64M65.58M
R&D as % of Total Revenue--63.34%99.11%169.21%--2802.11%1025.89%
Interest Expense174.00K106.00K--764.00K118.00K---
Interest Expense % of Total Revenue----5.43%----

Balance Sheet

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets19.79M44.55M223.22M264.72M185.36M73.74M221.66M226.24M113.51M
Total Liabilities49.43M89.06M55.86M72.23M54.53M172.77M51.75M65.83M62.07M
Total Equity-29.64M-48.28M167.36M192.49M130.82M-99.03M169.91M160.41M51.44M
Cash17.94M42.19M200.16M220.34M79.64M36.94M166.15M55.64M21.82M
Total Debt46.69M84.94M-45.99M45.60M166.99M33.21M44.77M43.49M
Net Debt28.76M42.75M-200.16M-174.35M-34.04M130.06M-132.94M-10.88M21.66M

Cash Flow

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-14.61M-17.02M34.22M-45.19M-32.09M-53.65M-67.28M-60.07M-78.56M
Investing Cash Flow-1.86M3.34M-18.26M10.40M-39.50M11.06M11.16M-123.35M43.99M
Financing Cash Flow27.98M37.94M142.01M56.69M115.94M18.00K187.76M69.36M685.00K
Capital Expenditure1.86M436.00K1.06M6.67M4.45M5.21M7.84M17.90M518.00K
Free Cash Flow-16.48M-17.46M33.15M-51.86M-36.54M-58.86M-75.12M-77.98M-79.08M
FCF to OCF112.75%102.56%96.89%114.76%113.86%109.72%111.65%129.80%100.66%

Earnings

Report DateSep 23, 2019Nov 18, 2019Mar 26, 2020May 14, 2020Aug 12, 2020Nov 16, 2020Mar 29, 2021May 13, 2021Aug 12, 2021Nov 15, 2021Mar 15, 2022May 4, 2022Aug 9, 2022Nov 8, 2022Mar 10, 2023May 12, 2023Aug 10, 2023Nov 2, 2023Mar 26, 2024May 14, 2024Aug 13, 2024Nov 12, 2024Mar 24, 2025May 7, 2025Aug 12, 2025Nov 12, 2025Mar 12, 2026May 7, 2026Aug 6, 2026Nov 11, 2026
EPS Estimate0.00-3.420.10-0.17-0.19-0.28-0.250.14-0.51-0.590.15-0.64-0.66-0.57-0.63-0.42-0.36-17.73-2.36-2.49-2.43-2.53-2.51-2.62-2.59-2.68-2.14-1.98-1.54-1.14
EPS Actual-0.28-0.73-0.19-0.16-0.19-0.16-0.30-0.60-0.52-0.73-0.62-0.67-0.61-0.55-0.49-0.55-0.30-15.50-25.65-2.44-2.43-2.26-2.26-2.49-2.74-1.92-1.65-1.69-1.07-
Surprise-78.66%-290.00%5.88%0.00%42.34%-18.11%-536.36%-2.24%-23.94%-506.02%-5.36%8.04%3.51%22.35%-30.95%16.67%12.58%-986.86%2.01%0.00%10.67%10.06%4.96%-5.79%28.36%22.90%14.73%30.52%-
Timing-----------------After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursAfter-hours-Pre-market-

Key Statistics & Ratios

Market Cap140.04M
Enterprise Value71.78M
Trailing P/E0.00
Forward P/E0.00
Price / Sales58.79
Price / Book1.40
EPS-9.88
Book Value7.02
Revenue (TTM)2.38M
Gross Profit (TTM)-41.02M
EBITDA-74.33M
Profit Margin0.00%
Operating Margin-3228.34%
Return on Equity-97.69%
Return on Assets-27.95%
Shares Outstanding14.73M
Shares Float10.58M
Beta2.25
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 10 analystsTarget 20.20
  • Strong Buy
    6
  • Buy
    4

Ownership Breakdown

Institutions
105.26%
Insiders
0.89%
Retail / Other
0.00%

Top Institutional Holders

  • Lynx1 Capital Management, LP
    1.54M10.45%
  • NEA Management Company, LLC
    1.30M8.81%
  • Balyasny Asset Management LLC
    1.04M7.06%
  • VR Adviser, LLC
    1.01M6.86%
  • Atlas Venture Life Science Advisors, LLC
    962.88K6.54%
  • Affinity Asset Advisors, LLC
    706.90K4.80%
  • Nantahala Capital Management, LLC
    660.04K4.48%
  • Adage Capital Partners Gp LLC
    540.97K3.67%
  • ADAR1 Capital Management LLC
    540.05K3.67%
  • BlackRock Inc
    460.01K3.12%
  • Driehaus Capital Management LLC
    450.05K3.06%
  • TCG Crossover Management, LLC
    416.30K2.83%
  • Siren, L.L.C.
    347.72K2.36%
  • Vanguard Capital Management, LLC
    310.91K2.11%
  • 72 Investment Holdings, LLC
    276.83K1.88%
  • AQR Capital Management LLC
    267.75K1.82%
  • Two Sigma Investments LLC
    178.07K1.21%
  • Geode Capital Management, LLC
    173.64K1.18%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    311.26K2.11%
  • iShares Russell 2000 ETF
    282.79K1.92%

Stock Splits

  • Nov 6, 20231:50